Dogwood Therapeutics Inc. has not released specific financial results in the provided document. However, a significant update involves a strategic transaction completed in Q4 2024, where Dogwood acquired Pharmagesic Holdings, including its novel pain development candidate, Halneuron®. As part of this transaction, CKLS, a publicly listed company on the Hong Kong exchange, received 211,383 shares of Common Stock and 2,108.3854 shares of Series A Preferred Stock, which is convertible into 10,000 shares of common stock each, pending shareholder approval. Additionally, a $20 million strategic financing loan from an affiliate of CK Life Sciences International was converted into 284.2638 shares of Series A-1 Preferred Stock in Q1 2025. Upon conversion of the Preferred Stock, CKLS and its affiliates will hold approximately 90% of Dogwood's common stock on a fully diluted basis. No specific guidance or outlook for sales, revenue, or profits has been disclosed in the document.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。